MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...

AV’s UES Awarded $75 Million Task Order Extending Contract to Advance Biotechnology and Smart Materials for the U.S. Air Force

The United States Air Force has awarded UES, a division of advanced research and development leader AeroVironment, Inc. ("AV" ...
Hosted on MSN

China’s Biotech Advances Threaten U.S. Dominance, Warns Congressional Report

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should invest ...
Business Wire

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting ® 2024

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of ...
Frontiers

Biohydrogel-Based Biomaterials for Next-Generation Tissue Repair

Recent years have witnessed extraordinary progress in tissue repair, driven primarily by innovations in biomaterial design and biofabrication. In ...